Smoking cessation

Keyphrases

• Pharmacotherapy 100%
• Smoking Cessation 100%
• Cigarette Smoking 66%
• Placebo 66%
• Quit Rate 66%
• Cannabinoid Receptor Antagonists 66%
• Lung Cancer 33%
• Chronic Obstructive Pulmonary Disease 33%
• Central Nervous System 33%
• Clinical Trials 33%
• Pathophysiology 33%
• On-state Current 33%
• Nicotine 33%
• Coronary Artery Disease 33%
• Platelet Aggregation 33%
• Oxidative Stress 33%
• Nicotinic Acetylcholine Receptor (nAChR) 33%
• Cocaine 33%
• Developing World 33%
• Non-pharmacological 33%
• Vascular Inflammation 33%
• Most Common Cause 33%
• Thrombus Formation 33%
• Epidemiology 33%
• Smoking Abstinence 33%
• Nicotine Replacement Therapy 33%
• Neurotransmitter Release 33%
• Pharmacological Therapy 33%
• Nicotine Dependence 33%
• Behavioral Therapy 33%
• Amphetamine 33%
• Opiates 33%
• Nortriptyline 33%
• Smoking Cessation Intervention 33%
• Clonidine 33%
• Therapy Approaches 33%
• Abstinence Rate 33%
• Varenicline 33%
• Bupropion 33%
• Quitters 33%
• Passive Smoking 33%
• Atherosclerotic Cardiovascular Disease (ASCVD) 33%
• Reduced Oxygen 33%
• Subject Characteristics 33%
• Secondary Complications 33%
• Oxygen Delivery 33%
• Coronary Vasodilation 33%
• Drug Approval 33%
• Heart Disease Risk 33%
• Active Smoke 33%
• Blood Coagulability 33%
• Platelet Thrombus 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Pharmacotherapy 100%
• Cigarette Smoking 50%
• Placebo 50%
• Cannabinoid Receptor Antagonist 50%
• Lung Cancer 25%
• Chronic Obstructive Lung Disease 25%
• Disease 25%
• Pathophysiology 25%
• Clinical Trial 25%
• Coronary Artery Disease 25%
• Thrombus 25%
• Nicotinic Receptor 25%
• Heart Disease 25%
• Neurotransmitter 25%
• Nortriptyline 25%
• Opiate 25%
• Clonidine 25%
• Varenicline 25%
• Tobacco Dependence 25%
• Coronary Artery Atherosclerosis 25%
• Vasculitis 25%
• Bupropion 25%
• Amphetamine Derivative 25%
• Coronary Artery Constriction 25%
• Drug Approval 25%
• Euphoriant 25%